TRUGLIF MET 12.5/1000MG TABLET

TRUGLIF MET 12.5/1000MG TABLET is a medication composed of two active ingredients: Empagliflozin & Metformin. Empagliflozin belongs to a class of medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors, while Metformin is a biguanide antidiabetic agent. This combination medication is used for the management of type 2 diabetes mellitus to help control blood sugar levels.

Ingredients:

1. Empagliflozin: An SGLT2 inhibitor that works by blocking the reabsorption of glucose in the kidneys, leading to increased urinary glucose excretion and lower blood sugar levels.
2. Metformin: A medication that reduces glucose production in the liver, improves insulin sensitivity in muscle cells, and decreases intestinal glucose absorption, thereby lowering blood sugar levels.

Uses:

TRUGLIF MET 12.5/1000MG TABLET is indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower blood sugar levels by promoting the excretion of glucose in the urine and reducing the amount of glucose produced by the liver. This medication is typically prescribed as an adjunct to diet and exercise to improve glycemic control in individuals with diabetes.

Administration:

TRUGLIF MET 12.5/1000MG TABLET is usually taken orally with a meal, as directed by a healthcare professional. The dosage may vary depending on individual factors such as the severity of diabetes, kidney function, and response to treatment. It is important to follow the prescribed dosage instructions provided by the healthcare provider to achieve optimal glycemic control.

Side Effects:

Common side effects of TRUGLIF MET 12.5/1000MG TABLET may include urinary tract infections, genital yeast infections, increased urination, thirst, nausea, vomiting, diarrhea, stomach upset, headache, and dizziness. These side effects are usually mild and temporary, but if they persist or worsen, individuals should consult their healthcare provider. Rare but serious side effects may include lactic acidosis and kidney problems. It is important to seek medical attention if any severe side effects occur.

Precautions:

Before using TRUGLIF MET 12.5/1000MG TABLET, individuals should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. This medication should be used with caution in individuals with kidney impairment, liver disease, heart failure, or a history of lactic acidosis. Regular monitoring of kidney function and blood sugar levels is recommended during treatment with TRUGLIF MET.

Contraindications:

TRUGLIF MET 12.5/1000MG TABLET is contraindicated in individuals with a known hypersensitivity or allergy to Empagliflozin, Metformin, or any of the components of the tablet. It should also be avoided in patients with severe kidney impairment, end-stage renal disease, metabolic acidosis, or a history of lactic acidosis. This medication should not be used in individuals with type 1 diabetes mellitus or diabetic ketoacidosis.

Conclusion:

TRUGLIF MET 12.5/1000MG TABLET, containing Empagliflozin and Metformin, is a combination medication used for the management of type 2 diabetes mellitus in adults. It helps lower blood sugar levels by promoting urinary glucose excretion and reducing hepatic glucose production. Individuals with type 2 diabetes should consult their healthcare provider to determine if TRUGLIF MET is an appropriate treatment option for them.